Robert F. Friel: Yeah, sure. So, it's targeted at three customers. First of all, our reproductive health area, and in that area I think there is a lot of cross-selling opportunity. So, I think as we talked about last quarter, our newborn screening business very often is reflexed into NGS for confirmatory testing. So, one of the things we're doing is we're now doing some of the confirmatory testing with our newborn screening customers. The other area where we see good synergies with our reproductive health business is in the ViaCord area where we have some 350,000 cords that are stored, and of course, ongoing business, where we see interest very often where those customers would like to have some whole genome sequencing done. So, I would say that's the first area that we're focused on. The second area was the one that I mentioned in the prepared remarks where we're doing work with IDG and they're having us do some whole genome sequencing with regard to neurological disorders. And then the third area I would mention would be in the pharmaceutical area, particularly in the orphan drug, where we're working with several pharmaceutical companies to help them particularly identify potential patients for clinical studies. So, I would say that's the initial focus of the business. We're seeing early days but good update. And while it's a startup right now, we do anticipate as we get the higher volume that we can get the operating margins equal to or maybe even a little bit better than the company average.
Robert F. Friel: So as I mentioned before, this is one of the first quarters in a while where we actually experienced growth in all three regions, so whether it's the Americas, EMEA or APAC. And so, if I look at each of those, I think the U.S., we continue to see generally pretty good growth across all areas with maybe the exception of academia was a little light. But other than that, we see good growth in Diagnostics. So, I would say if you look at newborn, first of all, while births now have sort of more flat in U.S., I would say prior to this quarter, we actually saw them down a little bit, we think, now. At the end of the third quarter, if you look on a trailing 12-month basis, it's more sort of flat. But our ability to continue to expand the menu and expand what we do, also mentioned the genetic testing business that we're now seeing good growth on the Diagnostics side, pharma continues to do well and the environmental and safety areas. So, I think good demand within the Americas. I think when you look at Europe, again, probably not as strong as U.S. but good strength on the pharma aside, I would say we saw a pickup on the industrial markets in Europe and food was very strong. And then, of course, the highest growth area for us was in APAC, obviously, led by China. China was up sort of mid-teens for us, and that was pretty strong across the board with possibly the exception of industrial, and that was really more of a comp issue. I think last year, if you look at China, our industrial business was up high-teens. So as I sort of mentioned in my prepared remarks, we're seeing pretty good strength, again, across the globe and across all the application areas.
Robert F. Friel: Yeah. I think, as you mentioned, that will be Europe first. I think it will be somewhat metered by the tenders. That's one of the things we're looking at relative to the potential for revenue in 2018 and we want to try and time that at least as best as we can to some of the tenders in some of these countries. So I think initially, if you look at 2018, that'll be a large determinant to how quickly it gets ramped up in the market. But again, the intention would be pretty broad based across Europe. Again, one of the important aspects of this is because this goes in, as we've talked about, into more of the biochemical markets, we've got a very strong commercial footprint in those markets already, basically, the leader in biochemical screening. So, we think this will be something we can penetrate relatively quickly. So, it will really be more gated by the timing of, again, the tenders, more than anything else. Again, just to remind, our plan is to have CE marked, so it will give us access the markets actually, other than just Western Europe.
Robert F. Friel: So, EUROIMMUN continues to do well. So if you look at the results through three quarters, they continue to grow organically in the high-teens area. I would say they're growing in 2017 in excess of what we assumed in the model. And so, one of the things we have been spending a fair amount of time on over the last several weeks is how we can be prepared to penetrate the U.S. market sort of as quickly as possible. And so, that will be clearly one of the top priorities that we've identified in the collaboration and synergy discussion. So, the plan would be to try and really drive growth in the U.S. relatively quickly.
Robert F. Friel: Yeah. So, you're right. The relationship historically was that we used the Waters mass spec in our solution. I mean, fundamentally, everything else that was in the solution, and again, when we service our customers, we go from the filter paper to the puncher to all of the sample preparation information to the detection information as far, and then, also the software and informatics. So moving forward now with the QSight, the plan would be to replace the Waters mass spec with the QSight. And so, going forward, it will be an exclusively 100% PerkinElmer solution.
Robert F. Friel: So, I would say if you look outside the developed markets, mass spec is relatively small from a penetration perspective. But of course, today, the developed markets are a large piece of it. So from an opportunity perspective, I would say roughly 30% of the market today is probably covered by mass spec, and again, the current market, and probably 70% is more biochemical. When you look at the opportunities going forward to expand the market, most of the emerging markets don't do mass spec today. They do just biochemical.
Robert F. Friel: So on the first one, yes, we continue to see penetration of incremental customers particularly outside the U.S. And so, I think that's a good significant component of the growth going forward. And on the second question is it's sort of early days there. I think that's a more significant opportunity for us going forward. So, we're hopeful, as we get into sort of 2018 and later, that we'll be able to get more pull-through on the PerkinElmer products.
Robert F. Friel: So, I think it's combination of things. And first of all, as we've been focused on new products, so we've got to get some new products out into the marketplace, and I mentioned I think over the last nine months or so, we've got 11 new imaging and detection products out in the marketplace (32:26). That's one. The other thing is I think disproportionately investing in those areas where I think we've got both greater growth opportunities and stronger competitive positions. And the ones I would specifically spike out would be food, in the pharma services area, some of our imaging capabilities, and maybe, finally, the inorganic applications like ICP and ICP-MS. So, making sure we're really sort of focusing in those areas. And then, the other area is just expanding our capabilities. So, I mentioned the fact that we just very recently opened up a manufacturing line in China for our DAS products. And I think locating more of our capabilities closer to our customers where else to be more nimble and respond more quickly, and also, starting to adopt more of our products to the needs of those specific geographic regions. So, I think those are the three key areas that I think we can sort of drive higher organic growth for DAS.
Robert F. Friel: Yeah. So, I think we felt like we got all, if not, 95% of the revenue that we missed in Q2. I think I mentioned last quarter is because the majority of the shortfall was on the instrument side, I think we felt actually by the latter part of July and maybe it spilled into early August, we had shipped all that. So, I think that was helpful to achieving our sort of the top end of our guidance relative to this quarter. I think relative to the areas we're seeing, I think it starts off with getting the traction on the new products, and so, that's driving food. I think we mentioned a couple or at least one nice win in OneSource, so I think that'll help us here in the fourth quarter as we start to ramp that program up. And I think some of the things that we've got in place on the Diagnostics side. I think we'll see it on the genetic testing side, some improvements, where we've got some expectations at QSight, starting to see some nice growth in the fourth quarter. So, we think we've got pretty good alignment to the growth targets that we've laid out for Q4.
Robert F. Friel: Yeah. I think there is. I mentioned before that we had a pretty tough comp in China relative to Q3 last year, it was up high-teens. So, I think a little bit of that was a comp issue. But I think your question implies that we're seeing some recovery in the industrial end markets and we would agree with that. So, I think we would be disappointed if we didn't see industrial start to pick up here, not only in Q4 but as we get into 2018.
Robert F. Friel: Steve, I'll take that. And that's a great question because it has been an important initiative of ours and a focus of ours. So if you look at new products, we started off the year and said, we're looking at about a $50 million help from new products, sort of incremental. And if you sort of track it through the year in the first quarter, we think it was in sort of the $13 million range. For the second quarter, it was about $21 million. We think the third quarter is maybe just a tad above that, maybe more like $22 million for the third quarter. So actually, through the nine months, we're now a little bit above our target of $50 million. So to your point, we feel good about the progress we're making here. And I think that, ultimately, is the lifeblood of our growth. The key is to make sure we're in attractive end markets and that we're bringing innovation to our customers to drive the incremental growth. And so, we continue to be very pleased with that. As we think about into 2018, I mean, we'll give 2018 guidance obviously, sort of in the earlier part of next year but we continue to be optimistic. And because as we get traction this year, it reinforces our confidence in, first of all, the process of how we're driving new products, and just as importantly, the team. So, the other aspect is over the last maybe 18 months, we have been upgrading the leadership of the R&D organization and it's great to see that it's making a difference.
Robert F. Friel: No. I mean, I think when we set the targets out for the 22% operating margin couple of years back, we targeted sort of 6%, 6.5% R&D spend. And I think year-to-date, we're at 6.3% or something like that. So, I think we're pretty comfortable with that number. And then, when you think about it relative to product revenue, it gets you up in the sort of 7.5%, almost 8% area. So, I think we're fine there now. Of course, with EUROIMMUN coming into the company, they do spend more as a percentage of R&D. So you will see, in fact, the R&D percentage go up, but I think that's just sort of a math exercise with EUROIMMUN coming in. But I think for the, I'll call it the historical PerkinElmer portfolio, I think where we are now seems pretty good relative to our ability to invest in the areas that we think are important and drive the organic growth that we've talked about.
Robert F. Friel: No. I don't think there's any bad guys in Diagnostics right now. I mean, generally, we feel like Diagnostics is on track to do the sort of 6% or 7% organic that we've talked about in the beginning of the year. I think the offsets are in the areas where we haven't sort of invested in the new products within DAS. So, we thought a fair amount about the organic portfolios, so ICP, ICP-MS, even AA. I think the areas that hopefully we'll be able to focus more on in 2018, in the areas like some of the chromatography areas, some of the areas around thermal and material characterization. So, I think there are some areas where we're probably may not making the – or we're not growing with the market because, again, we focus some of our investments in some of those other areas that support the food area or support pharma, et cetera.
Robert F. Friel: I would say if we include in recurring services, that would be basically the majority of the growth. I would say on a product basis, we were relatively flat, when you look at things like high content imaging doing well and a couple of other imaging products being offset by radiometric detection and sort of drug discovery. So, product was relatively flat. Services was the majority of the growth.
Robert F. Friel: Well, I'll start off by saying it's going to be impossible to replace Andy. But having said that, it's going well. I mean, it's early days. We've hired a search firm. We've seen some preliminary list of very qualified candidates. And so, I think we feel pretty good about the ability to get a very strong person in here. I think the nice thing is because of Andy's willingness to give us a fair amount of time, I think we should be in good shape as we get into sort of middle part of 2018.
Robert F. Friel: Yeah. So we continue to see strong growth in China, which is probably expected. We saw a particularly strength in Europe this quarter, very strong growth. And I think we just continue – I think it's a combination of we bought Perten, we bought Delta, we bought Bioo, and we've been in the process of trying to get those integrated, and then, also, leveraging some of the channel, historical channels of PerkinElmer and it sort of takes some time to do that and I think we're starting to see some nice traction there. And we're getting into some of the larger food customers and once we're in there, we're able to leverage additional products. So, either PerkinElmer products or pulling Perten and Delta through or vice versa.
Robert F. Friel: I would say we target food in sort of high single. I think in given quarters, we could probably see something in the teens. But I would say built into our Q4 guidance is food in the sort of low double-digit range.
Robert F. Friel: Great. Well, first of all, we appreciate your questions. And again, we feel good about our financial performance year-to-date, as well as the progress we continue to make on our strategic priorities. Thank you for your interest in PerkinElmer and have a great evening.
